###### Strengths and limitations of this study

-   This study provided a comprehensive assessment on the efficacy and safety of the pulsed electromagnetic field (PEMF) therapy in patients with knee, hand and cervical osteoarthritis (OA).

-   All included studies in this meta-analysis were randomised controlled trials.

-   There was a high level of heterogeneity among various studies, because different treatment protocols of PEMF were used in the included studies.

-   There were sparse eligible trials available for the efficacy analysis of hand OA and cervical OA, and the reliability of the conclusions on these two joints were limited.

Introduction {#s1}
============

Osteoarthritis (OA) is a widespread degenerative disease, which can lead to pain, physical dysfunction and even disability. The joints most commonly affected by OA include knees, hips, hands, neck and feet.[@R1] A variety of medications and physical therapies have been used in the treatment of OA. However, some widely applied drugs (eg, chondroitin, glucosamine, intra-articular hyaluronic acid, etc) or physical treatments (eg, transcutaneous electrical nerve stimulation and ultrasound) are actually not advocated by the recent Osteoarthritis Research Society International guidelines.[@R3] To date, few effective treatments for knee OA are available.

Since the early 1980s, researchers have found that pulsed electromagnetic field (PEMF) therapy could be applied to accelerate wound healing, repair fracture, reduce haematoma and treat soft tissue injury and inflammation.[@R4] In addition, some studies have demonstrated that PEMF could activate the signal transduction pathway[@R5] and induce the human articular chondrocyte proliferation.[@R8] Being a simple, non-invasive and safe physical therapy, PEMF was considered to be an alternative treatment regimen for OA. During the past two decades, more than 10 randomised controlled trials (RCTs) were conducted to explore the efficacy of PEMF in the treatment of OA, but no consensus was reached yet.[@R9] Several previous meta-analyses have evaluated the combined effects of PEMF and pulsed electrical stimulation (PES) on OA.[@R23] However, the mechanisms of PEMF and PES were totally different. For example, PES is delivered through capacitive coupling using transcutaneous electrodes and coupling agents[@R25] relying on the direct application of an electrical field, whereas PEMF creates induced current through magnetic impulse.[@R24] To the best of our knowledge, few meta-analyses have evaluated the efficacy and safety of single PEMF for OA.

To fill in this knowledge gap, the purpose of the present study was to provide a comprehensive assessment on the efficacy and safety of single PEMF in patients with OA at different joints. It was hypothesised that PEMF could relieve pain and improve the physical function of patients with OA without producing side effects.

Methods {#s2}
=======

Search strategies and studies selection {#s2a}
---------------------------------------

The study records were identified in four electronic databases of PubMed, Embase, the Cochrane Library and Web of Science through using the combination of a series of keywords and text terms describing OA and PEMF (see online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}). The latest literature search was conducted on 13 October 2017. Studies were included if: (1) subjects had symptomatic or radiographic OA, (2) the intervention contained PEMF versus sham--control, (3) the study was designed as an RCT, (4) the primary outcome included pain and/or function. Studies were excluded if: (1) experimental studies (eg, in vitro studies, animal studies or cadaveric studies), (2) studies for postoperation rehabilitation, (3) subjects treated by short wave or PES or any other physical therapies, (4) studies cannot get full text, (5) studies no data available, (6) unbalanced additional non-pharmacological treatments (eg, exercise or hot pack) between groups.
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Quality assessment {#s2b}
------------------

The methodological quality of each included trial was evaluated by two independent authors based on the Cochrane handbook,[@R26] which consists of seven domains: generation of randomisation sequences, allocation concealment, blinding of participants and implementers, blinding of outcome assessment, incomplete outcome data, selective reporting and other potential biases. Furthermore, any of divergence was to be discussed and a third consultant was needed if necessary.[@R28] Trials involving three or more high risks of bias were considered as poor methodological quality.[@R30]

Data extraction and outcome measure {#s2c}
-----------------------------------

All the data were extracted by two independent authors. The extracted information included the characteristics of participants (age, gender, body mass index and duration of OA), balance intervention between groups, number of participants in each trial, treatment protocol of PEMF and the type of outcome measures, baseline data, post-treatment data and mean changes and SD or the information from which SD could be derived, such as SE or CI. The primary goal of this study was to assess the efficacy of pain alleviation and function improvement by applying the PEMF therapy for patients with OA. Adverse events (AEs) were considered as the safety outcome. The efficacy of pain alleviation was measured by change of pain intensity from baseline.[@R31] Data at the last follow-up time point after treatment were extracted to calculate the change degree from baseline to the last follow-up. According to the recommended hierarchy of continuous pain-related outcomes used in the meta-analyses,[@R32] the outcome data expressed in higher ranking scale were extracted if multiple pain scale measured simultaneously. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function was the preferred measure for function outcome. If a study did not measure or report the WOMAC function, WOMAC total, Short Form-36 Health Survey (SF-36) social function score or total score and physician global assessment scores were used in the analysis instead.[@R34] The number of participants who reported AEs were also extracted in order to evaluate the safety of interventions.

Statistical analysis {#s2d}
--------------------

The Review Manager V.5.2 was used to perform all the statistical analyses. As the outcome of pain and function reported by continuous data and various scales were used for outcome assessment, the standardised mean differences (SMDs) were calculated to compare the effect of pain alleviation and function improvement between different intervention groups. For the safety outcome, the relative risk (RR) was calculated to compare the safety between the two groups. Trials that reported zero AE in both the PEMF and the sham groups were not included in the AEs analysis.[@R26] Ninety-five per cent CI was calculated for pooled estimates for each outcome. Statistical significance was considered at p\<0.05. A random model was applied to pool the data. Q and I[@R2] statistics were calculated to assess the heterogeneity among the included studies, with a p value \>0.05 of the Q statistics and I[@R2] value \<50% indicating statistical homogeneity. It is hypothesised that different exposure duration of PEMF and disease location will influence treatment effect. Therefore, subgroup analyses were performed according to the exposure duration of PEMF therapy (no more than 30 min per session or more than 30 min per session)[@R5] and location of OA. Funnel plots were inspected to assess publication bias.

Patient and public involvement {#s2e}
------------------------------

No patients or members of public were involved in the present study. No patients were asked to advise on the interpretation or writing up of results. The results of the present research will be communicated to the relevant patient community.

Results {#s3}
=======

Study screening and characteristics of included studies {#s3a}
-------------------------------------------------------

[Figure 1](#F1){ref-type="fig"} showed the flow diagram for study screening. One hundred and ninety-two records were identified initially and 12 studies[@R9] met the eligibility criteria and were included in this meta-analysis. The characteristics of included studies are summarised in [table 1](#T1){ref-type="table"}. The risk of bias assessment ([figure 2](#F2){ref-type="fig"}) showed that one study[@R9] was regarded as low quality.

![Flow chart of studies screening process based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline.](bmjopen-2018-022879f01){#F1}

![Risk of bias summary of 12 included studies. The green background with '+' means low risk of bias; the red background with '-' means high risk of bias; the yellow background with '?' means unknown risk of bias. Trials involving three or more high risks of bias were considered as poor methodological quality.](bmjopen-2018-022879f02){#F2}

###### 

Characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies                Balance            N                                               Location of OA   Age, years\          Female\            Mean BMI, kg/m^2^\   Duration of OA, years\   Exposure of intervention   Time point for outcome measure                           
                                                                                                             (mean±SD)            %                  (mean±SD)            (mean±SD)                                                                                                    
  ---------------------- ------------------ ----------------------------------------------- ---------------- -------------------- ------------------ -------------------- ------------------------ -------------------------- -------------------------------- ----------------------- -----------------------------------------------------------
  Ay[@R9]                PEMF               Hot pack, TENS                                  55               Knee                 58.9±8.8           70.0                 NA                       3.6±4.6                    30 min                           3 weeks\                After treatment
                                                                                                                                                                                                                                                               (15 sessions)           

  Placebo                57.7±6.5           76.0                                            NA               3.5±4.1                                                                                                                                                                   

  Bagnato[@R10]          PEMF               None                                            60               Knee                 67.7±10.9          70.0                 27.4±4.3                 12.1±8.2                   A minimum of 12 hours            1 month\                1 month
                                                                                                                                                                                                                                                               (30 sessions)           

  Placebo                68.6±11.9          73.3                                            27.7±4.6         12.4±9.1                                                                                                                                                                  

  Fischer[@R11]          PEMF               None                                            71               Knee                 52.1±1.9           71.4                 29.2±1.0                 6.8±0.7                    16 min                           6 weeks\                Therapy-end, 4 weeks after therapy-end
                                                                                                                                                                                                                                                               (42 sessions)           

  Placebo                62.1±1.5           72.2                                            29.4±0.7         6.2±0.6                                                                                                                                                                   

  Lee[@R13]              PEMF               None                                            51               Knee                 63.5±8.9           8.0                  26.1±3.1                 12.7±7.5                   30 min                           6 weeks (18 sessions)   3, 6 weeks during treatment, 4 weeks after finishing

  Placebo                66.2±8.8           11.5                                            27.1±3.7         12.8±7.6                                                                                                                                                                  

  Nelson[@R14]           PEMF               Current standard of care                        34               Knee                 55.5±2.5           73.7                 33.5±1.9                 NA                         15 min                           6 weeks\                14, 29, 42 days
                                                                                                                                                                                                                                                               (84 sessions)           

  Placebo                58.4±2.5           66.7                                            34.7±1.7         NA                                                                                                                                                                        

  Nicolakis[@R15]        PEMF               None                                            36               Knee                 69.0±5.0           73.3                 NA                       NA                         30 min                           6 weeks\                After treatment
                                                                                                                                                                                                                                                               (84 sessions)           

  Placebo                67.0±7.0           47.1                                            NA               NA                                                                                                                                                                        

  Pipitone[@R16]         PEMF               None                                            75               Knee                 62.0 (40--84) \*   35.3                 NA                       4.0 (1.0--18.0) \*         10 min and three times a day     6 weeks                 2, 4, 6 weeks after study entry

  Placebo                64.0 (48--84) \*   20.0                                            NA               8.0 (0.5--31.0) \*                                                                                                                                                        

  Tejero Sánchez[@R18]   PEMF               None                                            83               Knee                 67.4±8.7           87.9                 NA                       NA                         30 min                           20 sessions             The end of therapy, 1 month after therapy

  Placebo                68.0±8.3           88.2                                            NA               NA                                                                                                                                                                        

  Thamsborg[@R19]        PEMF               None                                            83               Knee                 60.4±8.7           46.5                 27.0±4.0                 7.5±5.2                    2 hours                          6 weeks\                2 weeks, end of treatment, 6 weeks after end of treatment
                                                                                                                                                                                                                                                               (30 sessions)           

  Placebo                59.6±8.6           61.0                                            27.5±5.7         7.9±7.7                                                                                                                                                                   

  Trock[@R20] †          PEMF               Do not change basic therapeutic regimen         86               Knee                 69.2±11.5          69.0                 NA                       9.1±8.9                    30 min                           4--5 weeks\             Midway of therapy, the last treatment, and 1 month later
                                                                                                                                                                                                                                                               (18 sessions)           

  Placebo                65.8±11.7          70.5                                            NA               7.4±7.2                                                                                                                                                                   

  Sutbeyaz[@R17]         PEMF               None                                            34               Cervical             43.2±10.3          64.7                 NA                       NA                         30 min                           3 weeks\                After treatment
                                                                                                                                                                                                                                                               (42 sessions)           

  Placebo                42.1±10.1          66.7                                            NA               NA                                                                                                                                                                        

  Trock[@R20] †          PEMF               Do not change basic therapeutic regimen         81               Cervical             61.2±13.4          28.6                 NA                       7.4±6.7                    30 min                           4--5 weeks\             Midway of therapy, the last treatment, and 1 month later
                                                                                                                                                                                                                                                               (18 sessions)           

  Placebo                67.4±8.0           30.8                                            NA               8.1±8.0                                                                                                                                                                   

  Kanat[@R12]            PEMF               Active range of motion and resistive exerciss   50               Hand                 64.0±2.60          NA                   NA                       5.01±2.3                   20 min                           10 days                 After treatment

  Placebo                62.0±2.40          NA                                              NA               4.31±4.7                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Age and duration of OA in this trial were expressed by median (range).

†This trial provided data of patients with knee OA and cervical OA, respectively.

BMI, body mass index; N, number of participates; NA, not available; OA, osteoarthritis; PEMF, pulsed electromagnetic field; TENS, transcutaneous electrical nerve stimulation.

Pain relief {#s3b}
-----------

Twelve RCTs were included for meta-analysis of pain management.[@R9] As shown in [figure 3](#F3){ref-type="fig"}, PEMF group achieved a significant difference in pain improvement compared with the sham group (SMD=−0.94, 95% CI −1.49 to --0.39, p=0.0008), while significant heterogeneity was observed (I^2^=92%; p\<0.00001). Subgroup analysis showed that significant differences were observed between the PEMF and sham group on pain improvement in patients with knee OA (SMD=−0.54, 95% CI −1.04 to --0.04, p=0.03) and hand OA (SMD=−2.85, 95% CI −3.65 to --2.04, p\<0.00001), whereas no significant difference was achieved between groups in patients with cervical OA (SMD=−2.33, 95% CI −6.26 to 1.61, p=0.25). As for subgroup analysis of different exposure duration, significant difference was observed with exposure duration within 30 min (SMD=−1.01, 95% CI −1.64 to --0.39, p=0.001), and no significant difference was achieved between intervention groups with exposure duration of more than 30 min (SMD=−0.61, 95% CI −2.25 to 1.02, p=0.46) (see [table 2](#T2){ref-type="table"}). Besides, substantial asymmetry was not identified in the funnel plot.

![Forest plot of pulsed electromagnetic field (PEMF) compared with sham--control on pain. Significant differences were observed between the PEMF and sham group on pain improvement in patients with knee osteoarthritis (OA) (p=0.03) and hand OA (p\<0.00001), whereas no significant difference was achieved between groups in patients with cervical OA (p=0.25).](bmjopen-2018-022879f03){#F3}

###### 

Results of subgroup analyses

  Reason for subgroup analyses   Pooled results of subgroups     Heterogeneity of subgroups               
  ------------------------------ ------------------------------- ---------------------------- ----------- --------
  Pain                                                                                                    
   Location                      Knee OA                         −0.54 (−1.04 to 0.04)        88          0.03
  Cervical OA                    −2.33 (−6.26 to 1.61)           97                           0.25        
  Hand OA                        −2.85 (−3.65 to 2.04)           NA                           \<0.00001   
   Exposure duration             No more than 0.5 hour/session   −1.01 (−1.64 to 0.39)        91          0.001
  More than 0.5 hour/session     −0.61 (−2.25 to 1.02)           95                           0.46        
  Function                                                                                                
   Location                      Knee OA                         −0.34 (−0.53, to 0.14)       0           0.0006
  Cervical OA                    −0.27 (−0.71 to 0.16)           NA                           0.22        
  Hand OA                        −1.49 (−2.12 to 0.86)           NA                           \<0.00001   
   Exposure duration             No more than 0.5 hour/session   −0.50 (−0.81 to 0.18)        59          0.002
  More than 0.5 hour/session     −0.33 (−0.82 to 0.17)           54                           0.20        
  Adverse event                                                                                           
   Exposure duration             No more than 0.5 hour/session   0.42 (0.14 to 1.29)          0           0.13
  More than 0.5 hour/session     1.95 (0.81 to 4.71)             NA                           0.14        

NA, not available.; OA, osteoarthritis; RR, relative risk; SMD, standard mean difference.

Function improvement {#s3c}
--------------------

Eight RCTs were included for meta-analysis of physical function improvement.[@R9] [Figure 4](#F4){ref-type="fig"} illustrated the beneficial effect of PEMF on physical function improvement (SMD=−0.45, 95% CI −0.71 to --0.19, p=0.0005), and substantial heterogeneity was observed (I^2^=54%; p=0.03). However, the subgroup analysis of different OA locations suggested significant differences both in knee OA and hand OA (SMD=−0.34, 95% CI −0.53 to --0.14, p=0.0006, and SMD=−1.49, 95% CI −2.12 to --0.86, p\<0.00001, respectively, see [table 2](#T2){ref-type="table"}), whereas there was no significant difference between groups in patients with cervical OA (SMD=−0.27, 95% CI −0.71 to 0.16, p=0.22). In addition, there was a significant difference on effect of function improvement with exposure duration within 30 min (SMD=−0.50, 95% CI −0.81 to 0.18, p=0.002), and no significant difference was observed in more than 30 min group (SMD=−0.33, 95% CI −0.82 to 0.17, p=0.20). Funnel plot also did not identify substantial asymmetry.

![Forest plot of pulsed electromagnetic field (PEMF) compared with sham--control on function. There were significant differences both in knee osteoarthritis (OA) (p=0.0006) and hand OA (p\<0.00001), whereas there was no significant difference between groups in patients with cervical OA (p=0.22).](bmjopen-2018-022879f04){#F4}

Adverse events {#s3d}
--------------

There were 10 RCTs that reported AEs.[@R9] Seven of them claimed that no AEs were observed both in PEMF and sham group.[@R9] Three trials reported the AEs of each treatment group, which mainly included increased knee pain, hip pain, spine pain, vomiting, warming sensation, increased blood pressure, numbness of feet, paraesthesia of foot and cardiomyopathy, and there were no AE-related dropouts in each trial.[@R11] There was no significant difference between the PEMF and the sham group regarding AEs (RR=0.83, 95% CI 0.26 to 2.64, p=0.75) ([figure 5](#F5){ref-type="fig"}). Substantial asymmetry was not identified in the funnel plot.

![Forest plot of pulsed electromagnetic field (PEMF) compared with sham--control on adverse events. There was no significant difference between the PEMF and the sham group regarding adverse events (p=0.75).](bmjopen-2018-022879f05){#F5}

Discussion {#s4}
==========

This study provided a comprehensive assessment of the scientific literature on the efficacy and safety of the PEMF therapy in patients with knee, hand and cervical OA. The results showed that, in comparison with the sham--control group, PEMF was more effective in both pain relief and function improvement for patients with knee OA and hand OA, but not for patients with cervical OA. In addition, PEMF did not lead to specific AEs compared with the sham--control group. Interestingly, a short duration of PEMF treatment for \<=30 min per session seems to achieve more favourable results. This finding may have significant implications for the clinical application of PEMF in the OA field.

As a non-invasive, safe and simple therapy, the PEMF therapy is widely used to treat soft injury and bone fracture and relieve pain and inflammation, as well as many other types of diseases and pathologies.[@R35] In the past two decades, researchers have turned their attention to the efficacy of treating OA. Some previous systematic reviews have combined PEMF and other physical therapies together to examine their efficacy in patients with OA, which might bias the results. McCarthy *et al* [@R36] demonstrated that PEMF and short wave together had limited effect in treating knee OA. In contrast, We *et al* [@R37] reported different results. Based on the follow-up data extracted from different time points for subgroup analysis, they concluded that the combination of PEMF and short wave was more effective in functional improvement, but not in pain relief, at 8 weeks after the first treatment.[@R37] It should be noted that short wave therapy was considered to be another type of physical therapy which was different from PEMF.[@R38] Similarly, another study conducted by Li *et al* [@R24] reported that PEMF and PES might provide moderate benefit for OA sufferers in terms of pain relief. However, considering that PES relies on the direct application of an electrical field and PEMF creates induced current through magnetic impulse, the combined analysis of these two physical therapies may also bias the results.

The results of the present study showed that PEMF had significant effects in pain alleviation and function improvement compared with the sham--control group in patients with knee and hand OA, but not in patients with cervical OA. The poor efficacy of the treatment for cervical OA may be due to the anatomical factors of cervical spine. The neurovascular structures contained in the cervical spinal canal may be compressed due to cervical OA, which will then induce a series of symptoms, such as the upper limb nerve root pain induced by nerve root compression, the chronic vertebral and basilar arterial insufficiency due to compression of vertebral arteries and the numbness of limbs and easiness to falling caused by spinal cord compression.[@R39] Although some studies showed that PEMF could enhance articular cartilage regeneration,[@R41] no evidence yet demonstrated that PEMF can reduce osteophytes formation, which may induce nerve root compression that can lead to deterioration of pain and function. In addition, the limited number of studies available is another reason that should not be ignored.

The present study further examined the association between the exposure duration of PEMF and efficacy for patients with OA. The results suggested that the exposure duration \<=30 min per session could achieve better efficacy both in pain relief and function improvement. The reason could be explained by several previous laboratory studies. A recent study exploring the effects of different PEMF treatment durations (ranged from 5 to 60 min) over the mesenchymal stem cell (MSC) chondrogenic differentiation reported that the expression of MSC chondrogenic markers showed the greatest increase in response to 5--20 min PEMF treatment.[@R43] Similarly, another two studies which have shown that PEMF could activate cellular signaling transduction rapidly within 5--10 min, whereas the signaling might be largely dulled after 30 min.[@R5]

Nevertheless, limitations of the present study should be acknowledged. First, since different treatment protocols of PEMF were used in the included studies, there was a high level of heterogeneity among various studies. Second, there were sparse eligible trials available for the efficacy analysis of hand OA and cervical OA, and the accuracy of the conclusions on these two joints were limited. In addition, because the number of studies reporting the pulse frequency of application, pulse intensity, pulsed rate and other parameters of PEMF was very limited, subgroup analyses were restricted according to these parameters of PEMF. Finally, morphological change is a meaningful outcome for exploring the treatment efficacy of PEMF further[@R19]; however, the morphological changes were not reported in the present study due to the lack of relevant data. More trials are needed to evaluate the morphological changes after PEMF therapy.

Conclusion {#s5}
==========

The present study revealed that PEMF could alleviate pain and improve physical function for knee and hand OA patients, but not for cervical OA. Meanwhile, a short PEMF treatment duration (within 30 min) may achieve more favourable efficacy. However, given the limited number of studies available in hand and cervical OA, the implication of this conclusion should be cautious for hand and cervical OA.
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